A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and ...

Ho Chi Minh Eye Hospital and Roche Pharma Vietnam are exploring cutting-edge solutions for patients suffering from retina ...

Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

Skin care aficionados everywhere are making space for a dermatologist-backed, budget-friendly brand in their medicine ...

Brian Roche – when the consultant becomes the bossHaving begun his public sector career as one of those highly paid ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

Some trails in the park in central Wisconsin reopened Friday to hikers days after a fire damaged stairway that leads to the ...

Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...